Mutations have been described in the V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase; these mutations cause the activation of the MAPK pathway and are usually present in up to 4% of patients with NSCLC, being much more frequent than other driver mutations in adenocarcinomas [101]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.